Helmholtz Centre for Infection Research GmbH, Braunschweig, Germany.
Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany.
Liver Int. 2017 Jan;37 Suppl 1:67-72. doi: 10.1111/liv.13320.
Despite an available vaccine and efficient treatment for hepatitis B virus (HBV) infection, chronic HBV infection still remains a major global threat, and one of the top 20 causes of human mortality worldwide. One of the major challenges in controlling HBV infection is the high number of undiagnosed chronic carriers and the lack of access to prophylaxis and treatment in several parts of the world. We discuss relevant barriers that need to be overcome to achieve global control of HBV infection and make eradication possible. Most important, vaccination must be scaled-up to lower the risk of vertical transmission and decrease the number of new infections, and comprehensive screening programs must be linked to care to obtain a better rate of diagnosis and treatment. This can probably only be achieved if sustainable funding is available. We therefore emphasize the importance of making the management of viral hepatitis a global health priority.
尽管有可用的乙型肝炎病毒 (HBV) 疫苗和有效的治疗方法，慢性 HBV 感染仍然是一个主要的全球威胁，也是全球 20 大死亡原因之一。控制 HBV 感染的主要挑战之一是全球许多地区存在大量未确诊的慢性携带者，以及无法获得预防和治疗。我们讨论了需要克服的相关障碍，以实现全球 HBV 感染控制并使其有可能被消除。最重要的是，必须扩大疫苗接种规模，以降低垂直传播的风险并减少新感染的数量，并且必须将全面的筛查计划与护理联系起来，以提高诊断和治疗的比例。如果有可持续的资金，这可能才能够实现。因此，我们强调将病毒性肝炎的管理作为全球卫生重点的重要性。
